Corona vaccine production makes for record year at AGC Biologics in Denmark
As Covid-19 vaccine orders flooded in, contract manufacturer AGC Biologics achieved a record year in 2021, during which Danish revenue surpassed USD 300m and the bottom line more than doubled.
by ulrich quistgaard, translated by catherine brett
The corona pandemic ended up being a good business opportunity for contract manufacturer (CDMO) AGC Biologics.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
